The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most frequent childhood malignancy. Treatment has been unified in the middle of 1980 in the Czech Republic. In 2002-2007 children and adolescents with acute lymphoblastic leukemia were treated in an international randomized trial ALL-IC BFM 2002 in the Czech Republic. 291 patients aged 1-18 years were enrolled; infants below 1 year entered a separate trial.
METHODS AND RESULTS: Patients were stratified into three risk groups according to their age, initial leukocyte count, prednisone response, presence of fusion genes BCR/ABL or MLL/AF4, bone marrow D+15 and remission status D+33. The whole therapy took 24 months. Randomized late intensification compared standard BFM therapy with extended, usually more intensive experimental treatment. The median follow-up was 8.7 years. Complete remission was achieved in 97.9% patients, 1% died in remission. 11% of children relapsed, 1.7% with CNS involvement. Six children (2.1%) developed secondary malignancy. Event free survival (EFS) 8 years from diagnosis was 83.5%, overall survival (OS) 91.4%. EFS and OS of the risk groups were: standard risk: 89.4%; 98.1%; intermediate risk: 82.6%; 89.6%; high risk: 68.8%; 78.1%. Male sex and age above 10 years were adverse prognostic factors.
CONCLUSIONS: In comparison with the previous trial ALL-BFM 95, significant improvement was achieved.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:154 |
|---|---|
| Enthalten in: |
Casopis lekaru ceskych - 154(2015), 2 vom: 21., Seite 79-89 |
| Sprache: |
Tschechisch |
|---|
| Weiterer Titel: |
Šance na vyléčení dětí s akutní lymfoblastickou leukémií stoupla v České republicev 21. století na 90 % - výsledky studie ALL IC-BFM 2002 |
|---|
| Beteiligte Personen: |
Zdráhalová, Kateřina [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 22.10.2015 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM249212803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM249212803 | ||
| 003 | DE-627 | ||
| 005 | 20231224153101.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||cze c | ||
| 028 | 5 | 2 | |a pubmed24n0830.xml |
| 035 | |a (DE-627)NLM249212803 | ||
| 035 | |a (NLM)25994910 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a cze | ||
| 100 | 1 | |a Zdráhalová, Kateřina |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial |
| 246 | 3 | 3 | |a Šance na vyléčení dětí s akutní lymfoblastickou leukémií stoupla v České republicev 21. století na 90 % - výsledky studie ALL IC-BFM 2002 |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 22.10.2015 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most frequent childhood malignancy. Treatment has been unified in the middle of 1980 in the Czech Republic. In 2002-2007 children and adolescents with acute lymphoblastic leukemia were treated in an international randomized trial ALL-IC BFM 2002 in the Czech Republic. 291 patients aged 1-18 years were enrolled; infants below 1 year entered a separate trial | ||
| 520 | |a METHODS AND RESULTS: Patients were stratified into three risk groups according to their age, initial leukocyte count, prednisone response, presence of fusion genes BCR/ABL or MLL/AF4, bone marrow D+15 and remission status D+33. The whole therapy took 24 months. Randomized late intensification compared standard BFM therapy with extended, usually more intensive experimental treatment. The median follow-up was 8.7 years. Complete remission was achieved in 97.9% patients, 1% died in remission. 11% of children relapsed, 1.7% with CNS involvement. Six children (2.1%) developed secondary malignancy. Event free survival (EFS) 8 years from diagnosis was 83.5%, overall survival (OS) 91.4%. EFS and OS of the risk groups were: standard risk: 89.4%; 98.1%; intermediate risk: 82.6%; 89.6%; high risk: 68.8%; 78.1%. Male sex and age above 10 years were adverse prognostic factors | ||
| 520 | |a CONCLUSIONS: In comparison with the previous trial ALL-BFM 95, significant improvement was achieved | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a acute lymphoblastic leukemia - children - chemotherapy - protocol ALL-IC BFM 2002. | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 650 | 7 | |a Vincristine |2 NLM | |
| 650 | 7 | |a 5J49Q6B70F |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Asparaginase |2 NLM | |
| 650 | 7 | |a EC 3.5.1.1 |2 NLM | |
| 650 | 7 | |a Thioguanine |2 NLM | |
| 650 | 7 | |a FTK8U1GZNX |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 650 | 7 | |a Daunorubicin |2 NLM | |
| 650 | 7 | |a ZS7284E0ZP |2 NLM | |
| 700 | 1 | |a Štěrba, Jaroslav |e verfasserin |4 aut | |
| 700 | 1 | |a Domanský, Jiří |e verfasserin |4 aut | |
| 700 | 1 | |a Blažek, Bohumír |e verfasserin |4 aut | |
| 700 | 1 | |a Ptoszková, Hana |e verfasserin |4 aut | |
| 700 | 1 | |a Mihál, Vladimír |e verfasserin |4 aut | |
| 700 | 1 | |a Novák, Zbyněk |e verfasserin |4 aut | |
| 700 | 1 | |a Hak, Jiří |e verfasserin |4 aut | |
| 700 | 1 | |a Procházková, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Černá, Zdena |e verfasserin |4 aut | |
| 700 | 1 | |a Timr, Pavel |e verfasserin |4 aut | |
| 700 | 1 | |a Jabali, Yahia |e verfasserin |4 aut | |
| 700 | 1 | |a Sedláček, Petr |e verfasserin |4 aut | |
| 700 | 1 | |a Smíšek, Petr |e verfasserin |4 aut | |
| 700 | 1 | |a Zemanová, Zuzana |e verfasserin |4 aut | |
| 700 | 1 | |a Jarošová, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Houdková, Alena |e verfasserin |4 aut | |
| 700 | 1 | |a Mejstříková, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Hrušák, Ondřej |e verfasserin |4 aut | |
| 700 | 1 | |a Zuna, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Janotová, Iveta |e verfasserin |4 aut | |
| 700 | 1 | |a Trka, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Starý, Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Casopis lekaru ceskych |d 1948 |g 154(2015), 2 vom: 21., Seite 79-89 |w (DE-627)NLM000001805 |x 0008-7335 |7 nnns |
| 773 | 1 | 8 | |g volume:154 |g year:2015 |g number:2 |g day:21 |g pages:79-89 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 154 |j 2015 |e 2 |b 21 |h 79-89 | ||